Bleeding Disorders & Anticoagulation Exam –
Bleeding Disorders & Anticoagulation Exam
Practice Exam 2026/2027 Practice Questions &
Study Guide | Complete Exam-Style Questions
with Correct Detailed Answers & Rationales
(Reliable Answers) | Latest Updated Version |
Instant Download PDf
Question 1
A patient with newly diagnosed hemophilia A has recurrent
hemarthroses. Laboratory testing shows a prolonged activated
partial thromboplastin time (aPTT), normal prothrombin time
(PT), and decreased factor VIII activity. Which treatment most
directly replaces the deficient coagulation factor?
A. Vitamin K
B. Protamine sulfate
C. Recombinant factor VIII concentrate
D. Fresh frozen plasma
Correct answer: C. Recombinant factor VIII concentrate
,Hemophilia A is caused by deficiency or dysfunction of
coagulation factor VIII. Recombinant factor VIII concentrates
directly replace the deficient factor and are the standard specific
replacement therapy for patients with significant bleeding or for
prevention of bleeding in severe hemophilia A. Vitamin K is used
for deficiencies of vitamin K–dependent factors, while
protamine reverses unfractionated heparin. Fresh frozen plasma
contains multiple coagulation factors but is generally not
preferred when a specific factor VIII concentrate is available.
Question 2
A patient taking warfarin has an INR of 7.2 but has no clinically
significant bleeding. What is the most appropriate general
management for a patient with markedly elevated INR without
bleeding?
A. Administer protamine sulfate immediately
B. Hold warfarin and reassess the INR
C. Administer idarucizumab
D. Give four-factor prothrombin complex concentrate routinely
Correct answer: B. Hold warfarin and reassess the INR
For a markedly elevated INR without clinically significant
bleeding, warfarin should generally be withheld and the INR
monitored. Management depends on the exact INR, bleeding
,risk, and clinical circumstances; low-dose oral vitamin K may be
considered at particularly high INR values or when bleeding risk
is increased. Protamine reverses heparin, not warfarin.
Idarucizumab specifically reverses dabigatran, while four-factor
prothrombin complex concentrate is generally reserved for
urgent reversal of serious or life-threatening warfarin-
associated bleeding or situations requiring rapid reversal.
Question 3
Which laboratory finding is most characteristic of disseminated
intravascular coagulation (DIC)?
A. Normal PT and aPTT with isolated thrombocytosis
B. Prolonged PT and aPTT with thrombocytopenia and elevated
D-dimer
C. Shortened PT with increased fibrinogen
D. Isolated prolonged bleeding time with normal platelet count
Correct answer: B. Prolonged PT and aPTT with
thrombocytopenia and elevated D-dimer
DIC involves widespread activation of coagulation, resulting in
consumption of platelets and coagulation factors and secondary
fibrinolysis. Typical laboratory findings include
thrombocytopenia, prolonged PT and aPTT, elevated D-dimer or
fibrin degradation products, and often a decreased fibrinogen
, concentration. The laboratory picture reflects simultaneous
pathologic clot formation and consumption of hemostatic
components, which can produce both thrombosis and bleeding.
Question 4
A patient receiving unfractionated heparin develops a platelet
count decrease of more than 50% approximately 7 days after
treatment begins. The patient also develops a new lower-
extremity thrombosis. What is the most likely diagnosis?
A. Immune thrombocytopenic purpura
B. Disseminated intravascular coagulation
C. Heparin-induced thrombocytopenia
D. Thrombotic thrombocytopenic purpura
Correct answer: C. Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is an immune-
mediated adverse reaction in which antibodies against platelet
factor 4–heparin complexes activate platelets. A platelet fall of
more than 50%, typically occurring 5–10 days after heparin
exposure, together with new thrombosis is highly suggestive.
Importantly, HIT is primarily a prothrombotic disorder rather
than simply a bleeding disorder. When HIT is suspected, heparin
should be discontinued and an appropriate non-heparin
anticoagulant initiated while diagnostic testing is pursued.
Bleeding Disorders & Anticoagulation Exam
Practice Exam 2026/2027 Practice Questions &
Study Guide | Complete Exam-Style Questions
with Correct Detailed Answers & Rationales
(Reliable Answers) | Latest Updated Version |
Instant Download PDf
Question 1
A patient with newly diagnosed hemophilia A has recurrent
hemarthroses. Laboratory testing shows a prolonged activated
partial thromboplastin time (aPTT), normal prothrombin time
(PT), and decreased factor VIII activity. Which treatment most
directly replaces the deficient coagulation factor?
A. Vitamin K
B. Protamine sulfate
C. Recombinant factor VIII concentrate
D. Fresh frozen plasma
Correct answer: C. Recombinant factor VIII concentrate
,Hemophilia A is caused by deficiency or dysfunction of
coagulation factor VIII. Recombinant factor VIII concentrates
directly replace the deficient factor and are the standard specific
replacement therapy for patients with significant bleeding or for
prevention of bleeding in severe hemophilia A. Vitamin K is used
for deficiencies of vitamin K–dependent factors, while
protamine reverses unfractionated heparin. Fresh frozen plasma
contains multiple coagulation factors but is generally not
preferred when a specific factor VIII concentrate is available.
Question 2
A patient taking warfarin has an INR of 7.2 but has no clinically
significant bleeding. What is the most appropriate general
management for a patient with markedly elevated INR without
bleeding?
A. Administer protamine sulfate immediately
B. Hold warfarin and reassess the INR
C. Administer idarucizumab
D. Give four-factor prothrombin complex concentrate routinely
Correct answer: B. Hold warfarin and reassess the INR
For a markedly elevated INR without clinically significant
bleeding, warfarin should generally be withheld and the INR
monitored. Management depends on the exact INR, bleeding
,risk, and clinical circumstances; low-dose oral vitamin K may be
considered at particularly high INR values or when bleeding risk
is increased. Protamine reverses heparin, not warfarin.
Idarucizumab specifically reverses dabigatran, while four-factor
prothrombin complex concentrate is generally reserved for
urgent reversal of serious or life-threatening warfarin-
associated bleeding or situations requiring rapid reversal.
Question 3
Which laboratory finding is most characteristic of disseminated
intravascular coagulation (DIC)?
A. Normal PT and aPTT with isolated thrombocytosis
B. Prolonged PT and aPTT with thrombocytopenia and elevated
D-dimer
C. Shortened PT with increased fibrinogen
D. Isolated prolonged bleeding time with normal platelet count
Correct answer: B. Prolonged PT and aPTT with
thrombocytopenia and elevated D-dimer
DIC involves widespread activation of coagulation, resulting in
consumption of platelets and coagulation factors and secondary
fibrinolysis. Typical laboratory findings include
thrombocytopenia, prolonged PT and aPTT, elevated D-dimer or
fibrin degradation products, and often a decreased fibrinogen
, concentration. The laboratory picture reflects simultaneous
pathologic clot formation and consumption of hemostatic
components, which can produce both thrombosis and bleeding.
Question 4
A patient receiving unfractionated heparin develops a platelet
count decrease of more than 50% approximately 7 days after
treatment begins. The patient also develops a new lower-
extremity thrombosis. What is the most likely diagnosis?
A. Immune thrombocytopenic purpura
B. Disseminated intravascular coagulation
C. Heparin-induced thrombocytopenia
D. Thrombotic thrombocytopenic purpura
Correct answer: C. Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is an immune-
mediated adverse reaction in which antibodies against platelet
factor 4–heparin complexes activate platelets. A platelet fall of
more than 50%, typically occurring 5–10 days after heparin
exposure, together with new thrombosis is highly suggestive.
Importantly, HIT is primarily a prothrombotic disorder rather
than simply a bleeding disorder. When HIT is suspected, heparin
should be discontinued and an appropriate non-heparin
anticoagulant initiated while diagnostic testing is pursued.
